Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response.

Pharmacotherapy - 1 Nov 2025

Moore Thomas J, Socal Mariana P, Anderson Gerard

Abstract excerpt

CONTEXT: To meet the need for effective treatments during the COVID-19 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments-a process that normally took 4-12 years. The government changed many features of the established system, selecting the investigational drugs, sponsoring or conducting the clinical testing, and purchasing and managing the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to COVID-19
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Development

Share to Drugs, Investigational

Share to Pandemics

Share to SARS-CoV-2

Share to United States Food and Drug Administration

Source

Open in PubMed Open full text

Identifiers

PMID: 41123220
DOI: 10.1002/phar.70070
PMCID: PMC12658407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response.PMID 41123220Read ↗

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Semantic proximity Read ↗

There Was No New Needle in the COVID Therapeutic Haystack A COVID-19 Therapeutics AnalysisSemantic proximity Read ↗

Review on different COVID-19 vaccines approved for Emergency Use Listing by WHO until 11 July 2022: characterization, pharmacological properties, mechanism of action and adverse events.Semantic proximity Read ↗

Projected resurgence of COVID-19 in the United States in July—December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccinationSemantic proximity Read ↗

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity Read ↗

Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.Semantic proximity Read ↗

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study.Semantic proximity Read ↗

Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity Read ↗

Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021Semantic proximity Read ↗

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel StrategiesSemantic proximity Read ↗

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antiviralsSemantic proximity Read ↗

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.